^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Angiopoietin 2 inhibitor

    Related drugs:
    7d
    MAGIC: Safety and Efficacy of Faricimab in Patients With NPDR (clinicaltrials.gov)
    P2, N=179, Completed, Greater Houston Retina Research | Active, not recruiting --> Completed
    Trial completion
    7d
    JADE: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (clinicaltrials.gov)
    P1, N=164, Completed, Ollin Biosciences, Inc.
    New P1 trial
    9d
    A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=93, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Mar 2027 --> Nov 2026
    Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    20d
    Two initial faricimab loading doses in treatment-naive neovascular AMD (2024-514408-15-00)
    P4, N=50, Active, not recruiting, Medical University Of Graz | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=93, Not yet recruiting, Genentech, Inc.
    New P1 trial
    1m
    Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • HEOR • Real-world evidence
    2ms
    Diabetic Macular Edema (DME) Patient Response to Faricimab and Associated Aqueous Humor Proteomic Differences Pre- and Post-Treatment (ChiCTR2500113982)
    P=N/A, N=154, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    3ms
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    3ms
    SHort Of Pace - Heart Failure (SHOP-HF) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Fundación para la Investigación del Hospital Clínico de Valencia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    L1-10
    4ms
    M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)
    P=N/A, N=117, Recruiting, Singapore National Eye Centre
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Lucentis (ranibizumab)
    4ms
    Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Nov 2027 --> Nov 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date • HEOR • Real-world evidence